The meeting between the president and U.S. health insurers on Monday was a chance for the industry to weigh in on promised changes to the Affordable Care Act that are beginning to come into focus.
Fishers-based Recovery Force LLC took a big step this month toward its goal of bringing to market a wrap that’s designed to improve blood flow and enhance recovery for people battling serious health issues.
Doubters about the $48 billion Anthem-Cigna merger have been in abundance from the start—both on antitrust grounds and on concerns over cultural fit.
Indiana House Republicans are taking the unusual step of reassigning an abortion bill to the same panel that narrowly approved it last week.
In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.
Indiana health care consulting executive Seema Verma on Thursday testified before the Senate Finance Committee on her nomination to lead the Centers for Medicare and Medicaid Services, or CMS.
Indianapolis-based Anthem Inc. on Wednesday won a court ruling blocking Cigna Corp. from terminating a proposed merger between the health insurers until a judge could weigh arguments over the faltering deal at an April 10 hearing.
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
In the lawsuit, Anthem blasted Cigna, accusing it of repeated efforts to sabotage their proposed merger.
Indianapolis-based Anthem responded almost immediately Tuesday by saying Cigna does not have the right to cancel the deal.
The Humana-Aetna deal was one of two mergers that would have reshaped the U.S. health insurance landscape. Both were rejected by federal judges as anticompetitive. Anthem hasn't given up on its deal—a $48 billion pact to acquire Cigna—and is pressing ahead with an appeal.
Two local men who have been working on a potential blockbuster treatment for a rare and debilitating disease are hopeful that a major injection of venture capital will provide the boost needed to move the drug to market—even if it means sweeping changes for their company.
Anthem filed a notice of appeal on Thursday after a federal judge blocked its $48 billion deal to buy Cigna Corp.
Vice President Mike Pence may have just picked another fight with pharmaceutical companies—one that doesn’t involve drug prices.
While Anthem said it was “significantly disappointed” by the judge’s order and would seek an expedited appeal, Cigna said only that it “intends to carefully review the opinion and evaluate its options in accordance with the merger agreement.”
The deal, along with Aetna Inc.’s proposed tie-up with Humana Inc., which was blocked last month, was set to reduce the ranks of big U.S. health insurers to three from five and make Anthem the largest by membership.
The closure of an Indianapolis residential care facility is expected to result in the loss of 87 jobs, but some of the workers might be able to land employment at the same company.
The Trump administration and its pick to lead the Centers for Medicare & Medicaid Services are likely to champion the approach behind HIP 2.0—a Medicaid expansion that requires those receiving insurance coverage to have "skin in the game" by contributing financially.
Eli Lilly and Co. CEO Dave Ricks said he was encouraged by President Donald Trump’s understanding of the complexities of drug development, yet he’s concerned about risks the industry may face in a fresh overhaul of the U.S. health-care system.
The company’s quarterly earnings announcement did not mention any new developments in the insurer’s pending, $54 billion acquisition of Cigna—which is under review by a federal judge.
